vimarsana.com

Latest Breaking News On - Sodium glucose cotransporter 2 inhibitors - Page 11 : vimarsana.com

Latin American Patients With Diabetes Prefer SGLT2 Inhibitors

Findings from a recent study highlight the need for clear discussions between patients and physicians before defining a treatment strategy.

Mexico cityDistrito federalLa plataBuenos airesUnited statesSusana vanoniCarmen castillo galindoNational universityLatin american diabetes associationPlata institute of cardiologySchool of medical sciencesLatin americanPatient preferenceEsteban costa gilCastillo galindoBetween june

Medicare Cost Sharing May Put Quadruple HF Therapy Out of Reach

Patients out-of-pocket costs are highest for the most effective medications.

United statesAnnac okellyKamilf faridiJasonh wasfyYale universityAmerican heart associationNational institutes of healthBoehringer ingelheimDrug administrationCenters for medicareInstitute for clinicalJournal of the american college cardiologyMedicaid servicesAmerican collegeNew havenMedicare advantage

Could a Type 2 Diabetes Drug Tackle Kidney Stones?

A pooled data analysis of trials of the SGLT2 inhibitor empagliflozin in type 2 diabetes suggests it may lower the risk of kidney stones. However, this is early research.

United statesNew havenKasperb kristensenPriyadarshini balasubramanianUniversity of southern denmarkYale school of medicineEndocrine society annual meetingInstitute of public healthDanish healthClinical endocrinologyYale schoolMedscape medicalData fromAdults withoutPublic healthClinical pharmacology

Positive Topline Results for Dapagliflozin in HFpEF: DELIVER

AstraZeneca says regulatory submissions will be forthcoming, potentially bringing a second SGLT2 inhibitor in this space, after empagliflozin.

United statesScott solomonHarvard medical schoolHeart failureSglt2 inhibitorsOdium glucose transporter 2 inhibitorsOdium glucose co transporter 2 inhibitorsSodium glucose cotransporter 2 inhibitorsCardiovascular imagingArdiac imagingV imagingEjection fraction efEft ventricular ejection fraction lvef

Combo of SGLT2 Inhibitor + GLP-1 RA Boosts Diabetes Survival

Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class alone.

United statesNew yorkBaylor college of medicineSalims viraniPersiod lopezUs veterans affairsNational va databaseAmerican college of cardiologyMichaele debakey va medical centerJamesj peters va medical centerAmerican collegeMount sinai morningsideHard to control diabetesBaylor collegeDiabetes mellitus type 2Iabetes mellitus type ii

vimarsana © 2020. All Rights Reserved.